Anthony M. Battram
A5054303521- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- CAR-T cell therapy research
- Chronic Myeloid Leukemia Treatments
- Peptidase Inhibition and Analysis
- Viral Infectious Diseases and Gene Expression in Insects
- Immune Cell Function and Interaction
- Research on Leishmaniasis Studies
- T-cell and B-cell Immunology
- Immunotherapy and Immune Responses
- Protein Kinase Regulation and GTPase Signaling
- Immunodeficiency and Autoimmune Disorders
- Biosimilars and Bioanalytical Methods
- Quinazolinone synthesis and applications
- Cell Adhesion Molecules Research
- Chronic Lymphocytic Leukemia Research
- CRISPR and Genetic Engineering
- Blood groups and transfusion
- PI3K/AKT/mTOR signaling in cancer
- Platelet Disorders and Treatments
- Telomeres, Telomerase, and Senescence
- Insect Resistance and Genetics
- RNA Interference and Gene Delivery
- Immune cells in cancer
- Lymphoma Diagnosis and Treatment
Hospital Clínic de Barcelona
2020-2024
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2020-2024
Universitat de Barcelona
2021-2024
Departament de Salut
2022
University of Bristol
2016
Abstract Purpose: B-cell maturation antigen (BCMA)-chimeric receptor T-cells (CART) improve results obtained with conventional therapy in the treatment of relapsed/refractory multiple myeloma. However, high demand and expensive costs associated CART might prove unsustainable for health systems. Academic CARTs could potentially overcome these issues. Moreover, response biomarkers resistance mechanisms need to be identified addressed efficacy patient selection. Here, we present clinical...
Chimeric antigen receptor (CAR)-T cell immunotherapy has revolutionized the treatment of B-lymphoid malignancies. For multiple myeloma (MM), B-cell maturation (BCMA)-targeted CAR-T cells have achieved outstanding complete response rates, but unfortunately, patients often relapse within a year receiving therapy. Increased persistence and reduced dysfunction are crucial features that enhance durability responses. One factors influence in vivo longevity loss function, which not yet been...
Background Chimeric antigen receptor (CAR)-T cell immunotherapy has modified the concept of treatment in hematological malignancies. In comparison with pediatric patients, where responses are maintained over many years, older such as those non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM), present lower persistence CAR-T cells that might be due to decreased fitness T acquired aging. Moreover, cord blood derived-NK (CB-NKs) CAR-NK derived from CB-NK can used ‘off-the-shelf’ immune...
Waldenström macroglobulinaemia (WM) is characterized by recurrent somatic mutations in MYD88 and CXCR4 genes. However, limitations arise when analysing these IgM monoclonal gammopathy of undetermined significance (MGUS) or smouldering WM (SWM) given the lower tumour load. Here, we used droplet digital polymerase chain reaction (ddPCR) to analyse L265P S338* (C1013G C1013A) unsorted bone marrow (BM) cell-free DNA (cfDNA) samples from 101 MGUS 69 SWM patients. ddPCR was more sensitive assess...
Autologous cell immunotherapy using B maturation antigen (BCMA)-targeted chimeric receptor (CAR)-T cells is an effective novel treatment for multiple myeloma (MM). This therapy has only been used relapsed and refractory patients, at which stage the endogenous T to produce CAR-T are affected by immunosuppressive nature of advanced MM and/or side effects previous therapies. An alternative pool "fitter" found in leukocytoapheresis products that routinely collected obtain hematopoietic...
Chimeric antigen receptor-T (CAR-T) cells directed against B-cell maturation (BCMA) are an effective treatment for multiple myeloma (MM), but short persistence and frequent relapses challenges this immunotherapy. This lack of durability has been attributed to the premature terminal differentiation CAR-T which prevents formation long-lived memory that maintain anti-tumour responses. To improve long-term efficacy, we used CRISPR/Cas9-mediated gene editing ablate expression transcription factor...
<div>AbstractPurpose:<p>B-cell maturation antigen (BCMA)-chimeric receptor T-cells (CART) improve results obtained with conventional therapy in the treatment of relapsed/refractory multiple myeloma. However, high demand and expensive costs associated CART might prove unsustainable for health systems. Academic CARTs could potentially overcome these issues. Moreover, response biomarkers resistance mechanisms need to be identified addressed efficacy patient selection. Here, we...
<div>AbstractPurpose:<p>B-cell maturation antigen (BCMA)-chimeric receptor T-cells (CART) improve results obtained with conventional therapy in the treatment of relapsed/refractory multiple myeloma. However, high demand and expensive costs associated CART might prove unsustainable for health systems. Academic CARTs could potentially overcome these issues. Moreover, response biomarkers resistance mechanisms need to be identified addressed efficacy patient selection. Here, we...
<p>Figure 13. Progression-free survival according to triple-refractoriness, high-risk cytogenetics, extramedullary involvement and ISS.</p>
<p>Figure 12. Time from measurable residual disease positivity to overt relapse</p>
<p>Figure 13. Progression-free survival according to triple-refractoriness, high-risk cytogenetics, extramedullary involvement and ISS.</p>
<p>Figure 10. Progression-free and overall survival according to cytokine values</p>
<p>Figure 11. Progression-free survival according to MRD-negative sensitivity on day 28.</p>
<p>Figure 10. Progression-free and overall survival according to cytokine values</p>
<p>Figure 11. Progression-free survival according to MRD-negative sensitivity on day 28.</p>
<p>Figure 14. Progression-free survival according to involved serum free-light chain levels below the lower limit of normality (green) on (A) days 28 and (B) 100.</p>
<p>Figure 12. Time from measurable residual disease positivity to overt relapse</p>
<p>Figure 1. Design of the study. Timeline lymphodepletion, ARI0002h fractionated infusion and booster dose.</p>
<p>Summary of the Study Protocol</p>
<p>Figure 14. Progression-free survival according to involved serum free-light chain levels below the lower limit of normality (green) on (A) days 28 and (B) 100.</p>